In a mouse model of imiquimod-induced psoriasis, inhibiting MCT4 with the MCT1/4 blocker, syrosingopine, partially alleviated psoriasis by disrupting the lactate-p65-NF-κB-MMP9 axis (8). This evidence concerns the gene SLC16A1 and psoriasis.